ABOUT THIS EPISODE
Drs Ursula A. Matulonis and Katherine Fuh discuss the molecular classification and genetics of endometrial cancer as well as when to rebiopsy, research updates, and what's to come in the future.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s2-ep3-2026a10008n7. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview
Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists https://pubmed.ncbi.nlm.nih.gov/37627129/
Molecular Testing for Endometrial Cancer: An SGO Clinical Practice Statement https://pubmed.ncbi.nlm.nih.gov/36399812/
TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/36232987/
Histopathological Characterization of ProMisE Molecular Groups of Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/31932106/
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02 https://pubmed.ncbi.nlm.nih.gov/39261417/
Randomized Phase III Trial of Radiation Therapy With or Without Pembrolizumab for Women With High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer (NRG-GY020) https://www.nrgoncology.org/Home/News/Post/randomized-phase-iii-trial-of-radiation-therapy-with-or-without-pembrolizumab-for-women-with-high-intermediate-risk-mismatch-repair-deficient-dmmr-endometrioid-endometrial-cancer-nrg-gy020
Testing Strategies for Lynch Syndrome in People With Endometrial Cancer https://www.medscape.co.uk/viewarticle/testing-strategies-lynch-syndrome-people-endometrial-cancer-2023a10001yb
Endometrial Cancer at Recurrence: To Re-sequence or Not to Re-sequence https://pubmed.ncbi.nlm.nih.gov/38841264/
Molecular Profiling of Primary Endometrioid Endometrial Cancer and Matched Lung Metastases: CTNNB1 Mutation as a Potential Driver https://pubmed.ncbi.nlm.nih.gov/38633674/
Route 66 Endometrial Cancer SPORE https://trp.cancer.gov/spores/abstracts/wustl_endometrial.htm
Project 2: Inhibiting AXL to Improve Treatment Response in Endometrial Cancer https://trp.cancer.gov/spores/abstracts/wustl_endometrial.htm#h04
AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA5515
Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer https://pubmed.ncbi.nlm.nih.gov/34884986/
GOG Foundation Overview https://www.gog.org/about/
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
